Denmark was the largest of Genmab A/S’s 4 reported lines in fiscal 2025, at $3.33B — 89% of $3.72B.
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Denmark | $2.33B | $2.87B | $3.33B | |||
| United States | $55.00M | $131.00M | $180.00M | |||
| Japan | $6.00M | $122.00M | $213.00M | |||
| Netherlands | — | — | $1.00M | |||
| Total | $2.39B | $3.12B | $3.72B |
In fiscal 2025, which ended December 31, 2025, the 4 regions Genmab A/S reported in this breakdown added up to $3.72B. The regions reported changed from fiscal 2024, so the total is not directly comparable with the $3.12B reported that year. Denmark was the largest region, at $3.33B or 89.4% of the total, followed by Japan ($213.00M, 5.7%) and United States ($180.00M, 4.8%). Together, the two largest regions made up 95.1% of this total.
Compared with fiscal 2024, Japan grew the fastest, rising 74.6% to $213.00M. Every sizeable region reported in both years grew. Because regions were added or dropped between the two years, part of this reflects how Genmab A/S regrouped its reporting.
Netherlands was first reported as a separate region in fiscal 2025. This breakdown covers 6 fiscal years between 2017 and 2025, as reported in Genmab A/S's annual filings.
Royalties was the largest of Genmab A/S’s 5 reported lines in fiscal 2025, at $3.10B — 83% of $3.72B.
| The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table. | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Royalties | $1.99B | $2.52B | $3.10B |
| Net Product Sales | $61.00M | $253.00M | $398.00M |
| Milestone Revenue | $171.00M | $145.00M | $97.00M |
| Reimbursement Revenue | $124.00M | $144.00M | $53.00M |
| Collaboration Revenue | $45.00M | $62.00M | $70.00M |
| Total | $2.39B | $3.12B | $3.72B |
In fiscal 2025, which ended December 31, 2025, the 5 revenue lines Genmab A/S reported in this breakdown added up to $3.72B. That was up 19.2% from $3.12B in fiscal 2024. Royalties was the largest revenue line, at $3.10B or 83.4% of the total, followed by Net Product Sales ($398.00M, 10.7%) and Milestone Revenue ($97.00M, 2.6%). Together, the two largest revenue lines made up 94.1% of this total.
Compared with fiscal 2024, Net Product Sales grew the fastest, rising 57.3% to $398.00M. Milestone Revenue fell the most, down 33.1% to $97.00M. Over fiscal 2023 to 2025, revenue across these revenue lines went from $2.39B to $3.72B, a compound annual growth rate of 24.8%. Royalties held a steady share of about 83.4%.
This breakdown covers every fiscal year from 2023 to 2025, as reported in Genmab A/S's annual filings.
Genmab A/S (GMAB) breaks its revenue down by region and revenue line. In fiscal 2025, its largest region was Denmark, with $3.33B or 89.4% of the total, followed by Japan at $213.00M (5.7%).
Denmark was Genmab A/S's largest region in fiscal 2025, with $3.33B in revenue, 89.4% of the $3.72B reported across its 4 regions.
Royalties was Genmab A/S's largest revenue line in fiscal 2025, with $3.10B in revenue, 83.4% of the $3.72B reported across its 5 revenue lines.
Of the Genmab A/S revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Net Product Sales grew the fastest, rising 57.3% from $253.00M to $398.00M.
Every figure is taken from Genmab A/S's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2017 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.